Anti-pd-l1 combinations for treating tumors

An immunotherapeutic and a PD-L/PD-1 Axis antagonist for use in combination therapy for treating a disease condition in a subject that is in need of such treatment, comprising administering to said subject an effective amount of said immunotherapeutic and an effective amount of said PD-L/PD-1 axis antagonist,

• wherein the immunotherapeutic is capable of activating a human plasmacytoid dendritic cell, myeloid dendritic cell, or NK cell, or a combination thereof, and is selected from the group consisting of resiquimod and imiquimod,
• wherein the PD-L/PD-1 Axis antagonist is an anti-PD-1 antibody or an anti-PD-L1 antibody,
• wherein the PD-L/PD-1 Axis antagonist and the immunotherapeutic are not linked to each other, and
• wherein the immunotherapeutic is administered to the subject as a pharmaceutical composition consisting of the immunotherapeutic and a pharmaceutically acceptable carrier.